Effects of Semaglutide combined with Insulin detemir in treatment of patients with obese type 2 diabetes mellitus with poor control of oral hypoglycemic drugs
Objective:To observe effects of Semaglutide combined with Insulin detemir in treatment of obese type 2 diabetes mellitus(T2DM)patients with poor control of oral hypoglycemic drugs.Methods:A prospective study was conducted on 85 obese T2DM patients with poor control of oral hypoglycemic drugs admitted to the hospital from June 2022 to September 2023.According to the random number table method,they were divided into study group(n=43)and control group(n=42),The control group was treated with Insulin detemir,while the study group was treated with Semaglutide on the basis of that of the control group.The clinical efficacy,the levels of glucose metabolism indexes[fasting blood glucose(FPG),glucagon-like peptide-1(GLP-1),2 h postprandial blood glucose(2hPG),glycosylated hemoglobin(HbA1c)],lipid metabolism indexes[triglyceride(TG),total cholesterol(TC),low-density lipoprotein(LDL-C),high-density lipoprotein(HDL-C)]and islet function indexes[fasting insulin(FINS),insulin resistance index(HOMA-IR)]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the study group was 90.70%(39/43),which was higher than 71.43%(30/42)in the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of FPG,2hPG and HbAlc in the two groups were lower than those before the treatment,and those in the study group were lower than those in the control group;the levels of GLP-1 in the two groups were higher than those before the treatment,and that in the study group was higher than that in the control group;and the differences were statistically significant(P<0.05).After the treatment,the levels of TG,TC and LDL-C in the two groups were lower than those before the treatment,and those in the study group were lower than those in the control group;the HDL-C levels of the two groups were higher than those before the treatment,and that in the study group was higher than that in the control group;and the differences were statistically significant(P<0.05).After the treatment,the FINS levels of the two groups were higher than those before the treatment,and that in the study group was higher than that in the control group;the HOMA-IR of the two groups was lower than that before the treatment,and that in the study group was lower than that in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Semaglutide combined with Insulin detemir can improve the total effective rate and the levels of glucose metabolism indexes,lipid metabolism indexes and islet function indexes in the obese T2DM patients with poor control of oral hypoglycemic drugs.Moreover,it is superior to simple Insulin detemir treatment.
SemaglutideInsulin detemirObese type 2 diabetes mellitusIslet functionGlucose metabolismLipid metabolismAdverse reaction
万方数据
维普
